Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | carboxylesterase 5A | 0.0445 | 0.5 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0445 | 0.5 | 0.5 |
Echinococcus granulosus | carboxylesterase 5A | 0.0445 | 0.5 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0445 | 0.5 | 0.5 |
Loa Loa (eye worm) | carboxylesterase | 0.0445 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0445 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0445 | 0.5 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0445 | 0.5 | 0.5 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0445 | 0.5 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0445 | 0.5 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.0445 | 0.5 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0445 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
(functional) | > 11.983 ug/ml | In vitro cytotoxicity evaluation on human fibroblasts measured by fluorescence after 72h | WHO/TDR. | No reference |
% motility reduction (functional) | = 0 % | Motility reduction assay in Schistosoma mansoni Egyptian sambon adult worms | WHO/TDR. | No reference |
% motility reduction (functional) | = 0 % | Motility reduction assay in Onchocerca ochengi microfilariae | WHO/TDR. | No reference |
% motility reduction (functional) | = 33.33 % | Motility reduction assay in vitro against Brugia malayi microfilariae at 10 uM | WHO/TDR. | No reference |
IC50 (functional) | = 0.388 ug/ml | In vitro activity against Leishmania infantum in mouse macrophages measured by cell viability after 5 days | WHO/TDR. | No reference |
IC50 (functional) | = 0.388 ug/ml | WHO-TDR: Leishmaniasis | ChEMBL. | No reference |
IC50 (functional) | > 11.983 ug/ml | In vitro activity against Plasmodium falciparum measured by colorimetry after 72h | WHO/TDR. | No reference |
IC50 (functional) | > 11.983 ug/ml | In vitro activity against Trypanosoma cruzi in human lung fibroblast measured by colorimetry after 7 days | WHO/TDR. | No reference |
IC50 (functional) | > 11.983 ug/ml | In vitro activity against Trypanosoma brucei measured by florescence after 24h | WHO/TDR. | No reference |
IC50 | > 11.983 ug/ml | WHO-TDR: Cytotoxicity | ChEMBL. | No reference |
IC50 (functional) | > 11.983 ug/ml | WHO-TDR: Chagas disease | ChEMBL. | No reference |
IC50 (functional) | > 11.983 ug/ml | WHO-TDR: Human African Trypanosomiasis (HAT) | ChEMBL. | No reference |
IC50 (functional) | > 11.983 ug/ml | WHO-TDR: Malaria | ChEMBL. | No reference |
Inhibition (functional) | = 0 % | WHO-TDR: Schistosomiasis | ChEMBL. | No reference |
Inhibition (functional) | = 33.33 % | WHO-TDR: Lymphatic Filariasis | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | ||
Leishmania infantum | ChEMBL23 | ||
Plasmodium falciparum | |||
Trypanosoma brucei gambiense | |||
Trypanosoma cruzi | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.